statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Buy Rating Affirmed for Cellectar Biosciences on Strong Clinical Results and Improved Financial Outlook

Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Cellectar Biosciences (CLRB Research Report) and keeping the price target at...

Buy Rating on Cellectar Biosciences Backed by Promising Drug Candidate and Solid Financials

Maxim Group analyst Jason McCarthy has reiterated their bullish stance on CLRB stock, giving a Buy rating today. Jason McCarthy has given his Buy r...

Q4 2023 Cellectar Biosciences Inc Earnings Call Transcript

Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript

Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript March 27, 2024
Cellectar Biosciences, Inc. isnt one of the 30 most popular stocks among hedge funds at the end of the...

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

Management to host a conference call today at 8:30 am ETFLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical...

Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript

Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript...

Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024

FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...

Cellectar Biosciences to Present at the 36th Annual Roth Conference

FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...

Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

Complete Remission rate of 64% and Overall Response Rate of 73% demonstrated in highly refractory patients Durability of clinical activity achieved 67% Overall Survival and 42% Progression Free...

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.

Volume	566,846.00
52-Wk High	$4.45
52-Wk Low	$1.56

CLRB Cellectar Biosciences Inc

About

Feed

News

Fundamentals